Update (June 13, 2026): Bedinvetmab Produces Equivalent OA Pain Control With Fewer Adverse Events Than Meloxicam in Head-to-Head RCT

TL;DR

An RCT comparing bedinvetmab monthly injection to once-daily oral meloxicam in dogs with OA found equivalent reductions in Canine Orthopaedic Index scores, but bedinvetmab produced substantially fewer adverse events (4 vs 17, nine of the meloxicam events being gastrointestinal).

What just dropped

• A 2025 Frontiers in Veterinary Science RCT enrolled 101 dogs with radiographically confirmed OA and randomised them to monthly bedinvetmab SC injection or once-daily oral meloxicam for 12 weeks. Both treatment arms produced statistically significant reductions in the Canine Orthopaedic Index (COI; p<0.001 in each group). (https://www.frontiersin.org/journals/veterinary-science/articles/10.3389/fvets.2025.1502218/full)
• Adverse events during the trial: 4 in the bedinvetmab arm vs 17 in the meloxicam arm, of which 9 meloxicam events were gastrointestinal. Completers were 44 (bedinvetmab) vs 33 (meloxicam). (https://www.frontiersin.org/journals/veterinary-science/articles/10.3389/fvets.2025.1502218/full)
• A separate non-inferiority study (Enomoto 2026, n=32) found FPGA treatment success at day 42 of 68.8% for bedinvetmab vs 56.3% for grapiprant, with a difference that did not exceed the pre-specified non-inferiority margin of 21.25%. (https://pubmed.ncbi.nlm.nih.gov/41667566/)

Context

Bedinvetmab (Librela) is an anti-NGF monoclonal antibody approved for control of OA pain in dogs. In contrast to NSAIDs, it does not inhibit cyclooxygenase enzymes and therefore carries no class-level risk of gastrointestinal or renal adverse effects from that mechanism. The 2025 head-to-head RCT provides direct comparative safety data against meloxicam, the most commonly used NSAID benchmark in canine OA research.

The lower dropout rate in the bedinvetmab arm (44 completers vs 33 for meloxicam) and the absolute difference in adverse event count are noteworthy in context: some practitioners have been cautious about bedinvetmab due to post-marketing musculoskeletal adverse-event signals reported from pharmacovigilance databases. The RCT, with its controlled population and 12-week observation period, provides a counterpoint showing a better short-term tolerability profile than meloxicam under those study conditions.

Taken alongside the Enomoto 2026 non-inferiority data against grapiprant, these studies support the position that bedinvetmab is clinically comparable to established OA analgesics on efficacy metrics while differing on the adverse event profile both in type and frequency.

What this changes in Bedinvetmab (Librela) Adverse Events in Dogs: Neurological Safety Profile (https://www.thevoyage.ai/forvets/knowledge/bedinvetmab-librela-adverse-events-dogs)

The direct head-to-head data against meloxicam add important context to the adverse event discussion on this page. The page covers post-marketing musculoskeletal and neurological signals; this RCT result shows the comparative short-term tolerability profile, which should be considered alongside pharmacovigilance findings when counselling owners and clinicians weighing treatment options.

References

1. Frontiers in Veterinary Science 2025. Bedinvetmab vs meloxicam randomised controlled trial in dogs with osteoarthritis. https://www.frontiersin.org/journals/veterinary-science/articles/10.3389/fvets.2025.1502218/full
2. Enomoto M et al. 2026. Non-inferiority of bedinvetmab vs grapiprant in dogs with OA: force-plate gait analysis study. PMID 41667566. https://pubmed.ncbi.nlm.nih.gov/41667566/

Related reads

• Bedinvetmab (Librela) Adverse Events in Dogs: Neurological Safety Profile
• Grapiprant (Galliprant) for Canine Osteoarthritis Pain: EP4 Antagonism and Clinical Evidence